Is nilotinib in combination with carboplatin and paclitaxel a candidate for ovarian cancer treatment?
Nilotinib may be a feasible targeted therapy option for the treatment of ovarian cancer.
Our data reveal a broad expression pattern of Bhlhb5 throughout retinogenesis and demonstrate the cell-autonomous as well as non-cell-autonomous role of Bhlhb5 in the specification of amacrine and bipolar subtypes.